Werewolf Therapeutics Inc’s filing revealed that its Shareholder MPM Asset Management Investors acquired Company’s shares for reported $7928.0 on Oct 27 ’25. In the deal valued at $1.77 per share,4,479 shares were bought.
Then, MPM BioVentures 2014 (B), L.P. bought 8,679 shares, generating $15,362 in total proceeds.
Before that, MPM Asset Management LLC bought 20,597 shares. Werewolf Therapeutics Inc shares valued at $36,457 were divested by the Shareholder at a price of $1.77 per share.
JMP Securities initiated its Werewolf Therapeutics Inc [HOWL] rating to a Mkt outperform in a research note published on April 03, 2024; the price target was $12. A number of analysts have revised their coverage, including Wedbush’s analysts, who began to cover the stock in late August with a ‘”an Outperform”‘ rating. BofA Securities started covering the stock on September 10, 2021. It rated HOWL as “a Buy”.
Price Performance Review of HOWL
On Monday, Werewolf Therapeutics Inc [NASDAQ:HOWL] saw its stock fall -4.52% to $1.69. Over the last five days, the stock has gained 4.32%. Werewolf Therapeutics Inc shares have fallen nearly -50.29% since the year began. Nevertheless, the stocks have risen 14.19% over the past one year. While a 52-week high of $3.26 was reached on 09/29/25, a 52-week low of $0.60 was recorded on 04/07/25.
Levels Of Support And Resistance For HOWL Stock
The 24-hour chart illustrates a support level at 1.6333, which if violated will result in even more drops to 1.5767. On the upside, there is a resistance level at 1.7883. A further resistance level may holdings at 1.8867.
How much short interest is there in Werewolf Therapeutics Inc?
A steep rise in short interest was recorded in Werewolf Therapeutics Inc stocks on 2025-10-15, growing by 1309.0 shares to a total of 0.82 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 0.82 million shares. There was a rise of 0.16%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 25, 2021 when SVB Leerink began covering the stock and recommended ‘”an Outperform”‘ rating along with a $29 price target.
